Not Medicare Enrolled
Dr. Sarah Fenton, M.D., PHD
Hematology & Oncology · Chicago, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Fenton from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Fenton?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Fenton
Dr. Sarah Fenton is a hematology & oncology specialist in Chicago, IL, with 10 years of NPI registration. Based on federal Medicare data, Dr. Fenton performed 14,650 Medicare services across 961 unique beneficiaries.
Between the years covered by Open Payments, Dr. Fenton received a total of $4,684 from 5 pharmaceutical and/or device companies across 8 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Fenton is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 10 years in practice
▲ Top 31% volume in IL
$4,684 industry payments
Medicare Practice Summary
Medicare Utilization ↗14,650
Medicare services
Top 31% in IL for hematology & oncology
961
Unique beneficiaries
$34
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,465 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 4,400 | $43 | $171 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
2,880 | $37 | $170 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
1,950 | $0 | $7 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
1,940 | $36 | $134 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
447 | $4 | $174 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
440 | $0 | $1 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
281 | $99 | $323 |
| Anti-nausea injection (Aloxi/palonosetron) | 280 | $1 | $76 |
| Injection, granisetron hydrochloride, 100 mcg | 260 | $0 | $5 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
252 | $90 | $821 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
245 | $4 | $10 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 198 | $134 | $2,712 |
| Cyclophosphamide, 100 mg | 152 | $16 | $111 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
134 | $108 | $940 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
123 | $13 | $143 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
80 | $100 | $250 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
66 | $28 | $237 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
63 | $17 | $129 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
60 | $53 | $410 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
57 | $66 | $217 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
52 | $24 | $203 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
46 | $12 | $88 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
41 | $129 | $505 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
37 | $60 | $326 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
34 | $8 | $20 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
34 | $54 | $464 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
32 | $23 | $215 |
| Injection, fludarabine phosphate, 50 mg | 22 | $257 | $977 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
17 | $1 | $4 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
15 | $105 | $472 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
12 | $1 | $7 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
15.6% high complexity
78.5% medium
5.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,684
Total received (2022-2024)
Avg $1,561/year across 3 years
Top 43% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
5
Companies
8
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,545 (54.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,907 (40.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$233 (5.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,451
2023
$96
2022
$136
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$1,907
Astellas Pharma Global Development
$1,727
Janssen Scientific Affairs, LLC
$818
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2022-2024) ›
PFIZER INC.
$1,919
Astellas Pharma Global Development
$1,727
Janssen Scientific Affairs, LLC
$818
AstraZeneca Pharmaceuticals LP
$124
EMD Serono, Inc.
$96
Top 3 companies account for 95.3% of all-time payments
Associated products mentioned in payments ›
BAVENCIO · LYNPARZA · PADCEV · Padcev · XTANDI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (54%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
326
Per 100K population
6.3
County median income
$81,797
Nearest hospital
NORTHWESTERN MEMORIAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | — Not enrolled | N/A |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Fenton is a mixed practice specialist, with moderate Medicare volume, with consulting-driven industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Fenton experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Fenton performed 4,400 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Fenton receive payments from pharmaceutical companies?
Yes. Dr. Fenton received a total of $4,684 from 5 companies across 8 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Fenton's costs compare to other hematology & oncology specialists in Chicago?
Dr. Fenton's average Medicare payment per service is $34. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Fenton) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Chicago
Browse hematology & oncology specialists in Chicago ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Astellas Pharma Global Development Payments to Doctors
See all physicians who received payments from Astellas Pharma Global Development.
By company
Janssen Scientific Affairs, LLC Payments to Doctors
See all physicians who received payments from Janssen Scientific Affairs, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology